Abstract is: Sir Mark Brian Pepys FRCP FRCPath FMedSci FRS (born 18 September 1944) is a South African-born British academic of medicine. He was until 2011 Professor of Medicine at University College London and Head of Medicine at the Hampstead Campus and the Royal Free Hospital.
| human | Q5 |
| P268 | Bibliothèque nationale de France ID | 123115312 |
| P2070 | Fellow of the Royal Society ID | 12078 |
| P646 | Freebase ID | /m/05p2pt2 |
| P213 | ISNI | 0000000030402108 |
| P244 | Library of Congress authority ID | n88096733 |
| P8189 | National Library of Israel J9U ID | 987007381129105171 |
| P856 | official website | http://iris.ucl.ac.uk/iris/browse/profile?upi=MBPEP52 |
| P496 | ORCID iD | 0000-0003-2614-3248 |
| P7293 | PLWABN ID | 9810674004005606 |
| P1153 | Scopus author ID | 56848974700 |
| P214 | VIAF ID | 316022870 |
| P10832 | WorldCat Entities ID | E39PBJjRRXjbCMddKRwtw6Trbd |
| P166 | award received | Harveian Oration | Q5676698 |
| Knight Bachelor | Q833163 | ||
| GlaxoSmithKline Prize | Q5567330 | ||
| Goulstonian Lectures | Q5588327 | ||
| Fellow of the Royal Society | Q15631401 | ||
| P27 | country of citizenship | United Kingdom | Q145 |
| P69 | educated at | Trinity College | Q332342 |
| UCL Medical School | Q7864086 | ||
| P108 | employer | University College London | Q193196 |
| P734 | family name | Pepys | Q70951405 |
| Pepys | Q70951405 | ||
| Pepys | Q70951405 | ||
| P735 | given name | Mark | Q13610143 |
| Mark | Q13610143 | ||
| P1412 | languages spoken, written or signed | English | Q1860 |
| P463 | member of | Royal Society | Q123885 |
| P106 | occupation | immunologist | Q12119633 |
| P21 | sex or gender | male | Q6581097 |
| Q70584371 | 'Amyloid degrading activity' of human serum, an in vitro clearing effect which does not involve degradation of amyloid fibrils |
| Q93564358 | A comparison of the erythrocyte sedimentation rate and serum C-reactive protein concentration in elderly patients |
| Q37342947 | A molecular correlate of clinicopathology in transthyretin amyloidosis |
| Q66913607 | A new immunoassay for C3. Application of the cell-linked antigen radioactive antibody (CLARA) technique |
| Q36159473 | A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis |
| Q74100148 | A novel variant of human lysozyme (T70N) is common in the normal population |
| Q72533090 | A novel variant of transthyretin, 59Thr-->Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family |
| Q67936225 | A pentameric form of human serum amyloid P component. Crystallization, X-ray diffraction and neutron scattering studies |
| Q45003207 | A primed state exists in vivo following histological regression of amyloidosis |
| Q42713859 | AL kappa amyloid in a solitary extradural lymphoma |
| Q42231070 | Acetazolamide and renal stone formation |
| Q46242773 | Activation of mouse complement by different classes of mouse antibody |
| Q71009481 | Acute phase protein response to infection in elderly patients |
| Q40162114 | Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. |
| Q73401915 | Acute phase proteins, C-reactive protein and serum amyloid A protein, as prognostic markers in the elderly inpatient |
| Q77397098 | Acute phase response and evolution of familial Mediterranean fever |
| Q41860893 | Acute-phase high-density lipoprotein in the rat does not contain serum amyloid A protein |
| Q71480789 | Agglutination of complement-coated erythrocytes by serum amyloid P-component |
| Q70320570 | Agglutination of intravenous lipid emulsion ('Intralipid') and plasma lipoproteins by C-reactive protein |
| Q36607480 | Amino acid sequence homology between rat and human C-reactive protein |
| Q70053158 | Amyloid (type AA) in a patient with hypogammaglobulinemia |
| Q64361059 | Amyloid P component and the diagnosis of amyloidosis |
| Q43689485 | Amyloid P component binds to keratin bodies in human skin and to isolated keratin filament aggregates in vitro |
| Q59080647 | Amyloid P component is located on elastic fibre microfibrils in normal human tissue |
| Q72621028 | Amyloid P-component in human glomerular basement membrane. Abnormal patterns of immunofluorescent staining in glomerular disease |
| Q46425380 | Amyloid P-component in mice injected with casein: identification in amyloid deposits and in the cytoplasm of hepatocytes. |
| Q36344195 | Amyloid P-component is a constituent of normal human glomerular basement membrane |
| Q41476788 | Amyloid and the gut. |
| Q34083986 | Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein |
| Q56336554 | Amyloidosis |
| Q72573267 | Amyloidosis |
| Q41647585 | Amyloidosis: a review of recent diagnostic and therapeutic developments |
| Q39550062 | Amyloidosis: some recent developments |
| Q67019594 | An improved method for the isolation from Naja naja venom of cobra factor (CoF) free of phospholipase A |
| Q41392379 | Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component |
| Q72691997 | Anti-keratin antibodies in rheumatoid arthritis: frequency and correlation with other features of the disease |
| Q34144814 | Antibodies to human serum amyloid P component eliminate visceral amyloid deposits |
| Q69863323 | Anticytoplasmic antibodies in Wegener's granulomatosis |
| Q57192740 | Association between C-reactive protein and features of the metabolic syndrome: a population-based study |
| Q37671921 | Attention to detail in the selection of words in epidemiologic research reports |
| Q47593388 | Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination? |
| Q36122263 | Bifunctional crosslinking ligands for transthyretin |
| Q28610043 | Binding of serum amyloid P-component (SAP) by amyloid fibrils |
| Q36348676 | Binding specificity of serum amyloid P component for the pyruvate acetal of galactose |
| Q40333621 | Biology of serum amyloid P component |
| Q40828366 | C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study |
| Q70367694 | C-reactive protein and apoB containing lipoproteins are associated with Mycobacterium leprae in lesions of human leprosy |
| Q33942651 | C-reactive protein and atherothrombosis |
| Q43901049 | C-reactive protein and bacterial infection in preterm infants |
| Q35562701 | C-reactive protein and cardiovascular disease: new insights from an old molecule |
| Q36562274 | C-reactive protein and cardiovascular disease: weighing the evidence |
| Q33883883 | C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction |
| Q43245383 | C-reactive protein and coronary disease: is there a causal link? |
| Q37281648 | C-reactive protein and coronary heart disease: a critical review |
| Q40668669 | C-reactive protein and its role in the pathogenesis of myocardial infarction. |
| Q34311841 | C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease |
| Q70394198 | C-reactive protein and serum amyloid P component in the plaice (Pleuronectes platessa L.), a marine teleost, are homologous with their human counterparts |
| Q85701251 | C-reactive protein and the acute phase response |
| Q70294453 | C-reactive protein and the acute phase response |
| Q44848809 | C-reactive protein as an index of disease activity. Comparison of tenidap, cyclophosphamide and dexamethasone in rat adjuvant arthritis |
| Q35182277 | C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis |
| Q72458568 | C-reactive protein fifty years on |
| Q40242821 | C-reactive protein in SLE. |
| Q33553961 | C-reactive protein in childhood dermatomyositis |
| Q69109634 | C-reactive protein in dogs |
| Q74316322 | C-reactive protein in healthy and in sick populations |
| Q51815178 | C-reactive protein in patients undergoing cardiac surgery. |
| Q33842663 | C-reactive protein is essential for innate resistance to pneumococcal infection |
| Q37101241 | C-reactive protein is neither a marker nor a mediator of atherosclerosis |
| Q71232764 | C-reactive protein levels in systemic lupus erythematosus: a classification criterion? |
| Q77855686 | C-reactive protein risk prediction: low specificity, high sensitivity |
| Q54002315 | C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. |
| Q40250788 | C-reactive protein. A review of its structure and function. |
| Q59384475 | C-reactive protein: a critical update |
| Q40202631 | C-reactive protein: the role of an ancient protein in modern rheumatology |
| Q81796168 | CRP or not CRP? That is the question |
| Q70331758 | Calcium-dependent aggregation of human serum amyloid P component |
| Q42249300 | Calcium-dependent aggregation of human serum amyloid P component. Inhibition by the cyclic 4,6-pyruvate acetal of galactose. |
| Q42878120 | Campylobacter pylori, duodenal ulcer disease, and gastrin |
| Q40921894 | Cell-mediated immunological responsiveness in mice decomplemented with cobra venom factor |
| Q70615552 | Circulating human C-reactive protein binds very low density lipoproteins |
| Q34528237 | Circulating human leucocyte elastase in patients with inflammatory bowel disease |
| Q44418527 | Circulating immunoglobulins and complement in mice with Hymenolepis nana infection |
| Q68986442 | Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits |
| Q47593403 | Classical and alternative pathway complement activation are not required for reactive systemic AA amyloid deposition in mice |
| Q77925656 | Clinical, radiological and serum amyloid P component scintigraphic features of beta2-microglobulin amyloidosis associated with continuous ambulatory peritoneal dialysis |
| Q34444888 | Common core structure of amyloid fibrils by synchrotron X-ray diffraction. |
| Q72609807 | Comparative analyses of pentraxins: implications for protomer assembly and ligand binding |
| Q45231646 | Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum |
| Q39560467 | Comparison of the role of complement in immunity to Schistosoma mansoni in rats and mice |
| Q67332077 | Complement dependence of localisation of aggregated IgG in germinal centres |
| Q42043743 | Complement factor H binds to denatured rather than to native pentameric C-reactive protein |
| Q50232959 | Complement independence of stimulation of mouse splenic B lymphocytes by mitogens |
| Q36091304 | Complement-independence of the acute-phase production of serum amyloijd P-component (SAP) in mice |
| Q70022054 | Complement-independence of tolerance induction |
| Q53850791 | Complement-mediated mixed aggregation of murine spleen cells. |
| Q48105954 | Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. |
| Q70072351 | Continuous subcutaneous insulin infusion does not induce a significant acute phase response of serum amyloid A protein |
| Q68860861 | Continuous subcutaneous insulin infusion does not provoke significant acute-phase response |
| Q72114120 | Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity |
| Q70406496 | Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate |
| Q69945990 | Correlation of disease activity in systemic vasculitis with serum C-reactive protein measurement. A prospective study of thirty-eight patients |
| Q73822126 | Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen alpha-chain variant in an English family |
| Q28247325 | Dame Sheila Patricia Violet Sherlock. 31 March 1918 - 30 December 2001 Elected FRS 2001 |
| Q71558073 | Delayed hypersensitivity reactions to Listeria monocytogenes in rats decomplemented with cobra factor and in C5-deficient mice |
| Q70242207 | Demonstration of amyloid A (AA) protein and amyloid P component (AP) in deposits of systemic amyloidosis associated with renal adenocarcinoma |
| Q44321077 | Detection of endotoxin in mice by measurement of endotoxin-induced changes in plasma concentrations of zinc and of the acute-phase protein serum amyloid P-component |
| Q57193287 | Determination of C-Reactive Protein: Comparison of Three High-Sensitivity Immunoassays |
| Q72575835 | Diagnosis of chest pain in marathon runners |
| Q69919964 | Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component |
| Q54557661 | Differences in the acute phase responses of serum amyloid P-component (SAP) and C3 to injections of casein or bovine serum albumin in amyloid-susceptible and -resistant mouse strains. |
| Q34529836 | Differing acute phase responses in Crohn's disease and ulcerative colitis |
| Q59691428 | Disease-associated prion protein is not detectable in human systemic amyloid deposits |
| Q28284799 | Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay |
| Q72520181 | Diurnal variation of erythrocyte sedimentation rate related to feeding |
| Q74725288 | Domino hepatic transplantation using the liver from a patient with familial amyloid polyneuropathy |
| Q73835723 | Echocardiographic assessment of cardiac involvement in systemic AL amyloidosis in relation to whole body amyloid load measured by serum amyloid P component (SAP) clearance |
| Q33938498 | Effect of alcohol consumption on systemic markers of inflammation |
| Q36249841 | Effect of ultraviolet radiation on production of epidermal cell thymocyte-activating factor/interleukin 1 in vivo and in vitro |
| Q69114882 | Effect of vitamin C dietary supplementation on survival in amyloidosis |
| Q39316920 | Effects of human chorionic gonadotropin preparations on complement in vitro |
| Q58230329 | Enhanced Inflammatory Response to Coronary Angioplasty in Patients With Severe Unstable Angina |
| Q58230307 | Enhanced inflammatory response in patients with preinfarction unstable angina |
| Q67498746 | Enumeration of immunoglobulin-bearing lymphocytes in whole peripheral blood |
| Q36831487 | Enumeration of lymphocyte populations in whole peripheral blood with alkaline phosphatase-labelled reagents. A method for routine clinical use. |
| Q70732435 | Epileptic discharges produced in monkeys by injection of spleen cells from rabbits immunised with monkey brain |
| Q46363906 | Equilibrium contrast CMR for the detection of amyloidosis in mice |
| Q34351246 | Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component |
| Q69089808 | Experimental amyloidosis in the hamster: correlation between hamster female protein levels and amyloid deposition |
| Q70437789 | Familial amyloidosis of Ostertag |
| Q41897872 | Fibronectin and C4-binding protein are selectively bound by aggregated amyloid P component |
| Q40547674 | Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins |
| Q40764357 | Glycobiology of the pentraxins |
| Q45763805 | Haemodialysis versus CAPD: equal predisposition to amyloidosis? |
| Q43084777 | Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man. |
| Q37356259 | Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene |
| Q74165052 | Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I |
| Q73114907 | Hereditary renal amyloidosis associated with variant lysozyme in a large English family |
| Q27681150 | Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin |
| Q34167746 | Hormone binding globulins undergo serpin conformational change in inflammation |
| Q50102155 | Human C-reactive protein does not protect against acute lipopolysaccharide challenge in mice |
| Q47400800 | Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats |
| Q34362632 | Human lysozyme gene mutations cause hereditary systemic amyloidosis |
| Q47586967 | Human plasma fibrinogen is synthesized in the liver |
| Q24290183 | Human serum amyloid P component is a single uncomplexed pentamer in whole serum |
| Q35501399 | Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure |
| Q33370591 | Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: therapeutic implications for hemolytic-uremic syndrome |
| Q28362275 | Human serum amyloid P component, a circulating lectin with specificity for the cyclic 4,6-pyruvate acetal of galactose. Interactions with various bacteria |
| Q69123750 | Identification and isolation of two pentraxins from bovine serum |
| Q41958594 | Imaging amyloidosis in Still's disease |
| Q28284916 | Imaging amyloidosis with radiolabelled SAP |
| Q69464216 | Imaging of experimental amyloidosis with 131I-labeled serum amyloid P component |
| Q68309481 | Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component |
| Q70359591 | Immunochemical cross-reactions between pentraxins of different species |
| Q66919419 | Immunodeficiency, malabsorption and secretory diarrhea. A new syndrome |
| Q70364417 | Immunohistochemical demonstration of amyloid P component in cerebro-vascular amyloidosis |
| Q70180774 | Immunohistochemical demonstration of amyloid P component in skin of normal subjects and patients with cutaneous amyloidosis |
| Q69886670 | Immunohistochemical studies of C-reactive protein and apolipoprotein B in inflammatory and arterial lesions |
| Q36599566 | Immunohistochemical studies of amyloid P component and fibronectin in erythropoietic protoporphyria |
| Q70239130 | Immunohistochemical studies of amyloid P component distribution in normal human skin |
| Q71443651 | Immunohistochemical studies of amyloid P component in disorders of cutaneous elastic tissue |
| Q39720723 | Immunological studies in inflammatory bowel disease |
| Q84453752 | Immunoradiometric assay for human serum amyloid P component |
| Q40757294 | Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. |
| Q67443577 | Immunosuppression by cobra factor: distribution, antigen-induced blast transformation and trapping of lymphocytes during in vivo complement depletion |
| Q51235572 | Immunotherapeutic clearance of systemic amyloid deposits by antibodies to serum amyloid P component. |
| Q93606149 | In vivo turnover studies of C-reactive protein |
| Q70615558 | In vivo turnover studies of C-reactive protein and lipoproteins in the rabbit |
| Q72993224 | Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system |
| Q35830611 | Induction in mice of human light-chain-associated amyloidosis. |
| Q57193336 | Infection With Helicobacter pylori Is Not a Major Independent Risk Factor for Stable Coronary Heart Disease |
| Q40434935 | Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability |
| Q36087895 | Influenza virus infection is not affected by serum amyloid P component. |
| Q34391885 | Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers |
| Q69369344 | Inhibition by C3 fragments of C3-dependent rosette formation and antigen-induced lymphocyte transformation |
| Q41956962 | Inhibition of complement-dependent rosette formation after lymphocyte incubation with fatty acids |
| Q33671132 | Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel. |
| Q27734827 | Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis |
| Q68139548 | Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient |
| Q27684907 | Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC) |
| Q41839042 | Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component |
| Q84883848 | Invasive candidiasis: new insights presaging new therapeutic approaches? |
| Q94507908 | Is leptin an important physiological regulator of CRP? |
| Q70336051 | Is the serum amyloid A protein in acute phase plasma high density lipoprotein the precursor of AA amyloid fibrils? |
| Q70330850 | Isolation and characterisation of goat C-reactive protein |
| Q51838674 | Isolation and characterization of C-reactive protein from the dog. |
| Q46987180 | Isolation and characterization of guinea-pig serum amyloid P component |
| Q33796862 | Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. |
| Q41873333 | Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils. |
| Q67714062 | Isolation and study of murine C3 |
| Q39181928 | Isolation of C-reactive protein by affinity chromatography |
| Q39433913 | Isolation of amyloid P component (protein AP) from normal serum as a calcium-dependent binding protein |
| Q50936106 | Isolation of human C-reactive protein and serum amyloid P component. |
| Q66960978 | Isolation of serum amyloid P-component (protein SAP) in the mouse |
| Q48515561 | Jack Pepys (May 15, 1914-September 9, 1996): a personal recollection |
| Q36763917 | Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis |
| Q77678991 | Lack of seasonal variation in C-reactive protein |
| Q40778009 | Left atrial myxoma associated with systemic AA amyloidosis |
| Q39464110 | Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. |
| Q58787971 | Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease |
| Q36346658 | Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein |
| Q33910496 | Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses |
| Q73284286 | Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease |
| Q41034217 | Lymphocyte binding of fluid phase mouse C3b. |
| Q40605429 | MHC typing in variant Creutzfeldt-Jakob disease. |
| Q73892920 | Markers of inflammation in women on different hormone replacement therapies |
| Q37180014 | Measurement of serum C reactive protein concentration after bone marrow transplantation for leukaemia |
| Q34056876 | Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction |
| Q42739612 | Measurement of serum amyloid A protein concentrations as test of renal allograft rejection |
| Q58313015 | Mechanisms of Schistosoma mansoni egg excretion: Parasitological observations in immunosuppressed mice reconstituted with immune serum |
| Q33895058 | Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease |
| Q35817146 | Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis |
| Q55670644 | Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis |
| Q22254102 | Molecular chaperone properties of serum amyloid P component |
| Q70754283 | Molecular characterization of Limulus polyphemus C-reactive protein. I. Subunit composition |
| Q38319142 | Molecular characterization of Limulus polyphemus C-reactive protein. II. Asparagine-linked oligosaccharides |
| Q38450940 | Monitoring systemic amyloidosis using MRI measurements of the extracellular volume fraction |
| Q39628452 | Monitoring the acute phase response to vaso-occlusive crisis in sickle cell disease |
| Q43134825 | Multinucleated Giant Cells Are Specialized for Complement-Mediated Phagocytosis and Large Target Destruction |
| Q69609359 | Murine type II collagen arthritis. Association of an acute-phase response with clinical course |
| Q70714883 | Myelosclerosis and paroxysmal nocturnal haemoglobinuria |
| Q45851323 | New therapeutic perspectives – amyloid removal |
| Q73441568 | Nine novel L1 CAM mutations in families with X-linked hydrocephalus |
| Q72582381 | Non-invasive demonstration of cardiac involvement in acquired forms of systemic amyloidosis |
| Q80388314 | Normal circulating serum amyloid P component concentration in systemic sclerosis |
| Q44927103 | Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences |
| Q70584391 | Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration |
| Q34551909 | Objective monitoring of disease activity in polyarteritis by measurement of serum C reactive protein concentration |
| Q71525763 | Occult adrenal insufficiency secondary to amyloidosis in the context of chronic renal failure |
| Q58853184 | Organ Transplantation in Hereditary Apolipoprotein AI Amyloidosis |
| Q34208267 | Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy |
| Q74146042 | Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study |
| Q34190813 | Pathogenesis, diagnosis and treatment of systemic amyloidosis |
| Q37218553 | Pathogenetic mechanisms of amyloid A amyloidosis. |
| Q73770055 | Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses |
| Q42938095 | Pentraxin-chromatin interactions: serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin |
| Q36635583 | Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo |
| Q40333638 | Phylogenetic aspects of C-reactive protein and related proteins |
| Q58230366 | Plasma Protein Acute-Phase Response in Unstable Angina Is Not Induced by Ischemic Injury |
| Q72705424 | Plasma haemostatic factors and diabetic retinopathy |
| Q39462049 | Plasma leucocyte elastase concentrations in smokers |
| Q71005590 | Plasma levels of inhibitor-bound leukocytic elastase in rheumatoid arthritis patients |
| Q68502510 | Preparative isolation of human beta 2-microglobulin from urine |
| Q47336910 | Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting |
| Q37325273 | Primary localised amyloidosis of the orbit |
| Q71443655 | Primary localized cutaneous amyloidosis: dermal amyloid deposits do not bind antibodies to amyloid A protein, prealbumin or fibronectin |
| Q72588493 | Primary localized orbital amyloidosis composed of the immunoglobulin gamma heavy chain CH3 domain |
| Q45041020 | Proceedings: Antigen binding cells in rabbit Peyer's patches after intestinal immunisation |
| Q67355346 | Proceedings: Complement dependence of IgA antibody production |
| Q34064191 | Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group |
| Q44049989 | Production of granulocyte colony-stimulating factor in the nonspecific acute phase response enhances host resistance to bacterial infection |
| Q77078349 | Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis |
| Q34446461 | Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself |
| Q37713382 | Protection of human podocytes from shiga toxin 2-induced phosphorylation of mitogen-activated protein kinases and apoptosis by human serum amyloid P component |
| Q27681502 | Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis |
| Q74453988 | Pyrin/marenostrin mutations in familial Mediterranean fever |
| Q72729382 | Quantitation of human leukocyte elastase, cathepsin G, alpha-2-macroglobulin and alpha-1-proteinase inhibitor in osteoarthrosis and rheumatoid arthritis synovial fluids |
| Q71067575 | Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease |
| Q42936828 | Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins |
| Q72613887 | Radioimmunoassay for immunoconglutinins |
| Q70597104 | Radiometric ligand binding assay for C-reactive protein. Complexed C-reactive protein is not detectable in acute phase serum |
| Q72019077 | Rapid automated enzyme immunoassay of serum amyloid A |
| Q47980173 | Rapid automated high sensitivity enzyme immunoassay of C-reactive protein |
| Q54422782 | Real-time measurement of serum C-reactive protein in the management of infection in the elderly. |
| Q44547380 | Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies, 1984 and 1987. |
| Q53864394 | Relationship of granulocyte colony stimulating factor with other acute phase reactants in man. |
| Q73096580 | Renal transplantation for amyloid end-stage renal failure-insights from serial serum amyloid P component scintigraphy |
| Q47234415 | Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis |
| Q72083045 | Rheumatoid Arthritis: The Role of Acute-Phase Proteins |
| Q77850230 | Risk factors for coronary heart disease and acute-phase proteins. A population-based study |
| Q47827690 | Role of C3 in in vitro lymphocyte cooperation. |
| Q34212341 | Role of Complement in Induction of the Allergic Response |
| Q41921458 | Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses |
| Q40621310 | Role of complement in the induction of immunological responses |
| Q71455608 | Role of heart transplantation in systemic amyloidosis |
| Q35850904 | Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen |
| Q50214635 | Role of the acute phase response in the Shwartzman phenomenon |
| Q74483154 | SAA1 alleles as risk factors in reactive systemic AA amyloidosis |
| Q34735776 | Science and serendipity |
| Q47851186 | Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis |
| Q34340365 | Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression |
| Q48376813 | Scintigraphy with 123I-serum amyloid P component in Alzheimer disease. |
| Q52626284 | Secondary structure prediction of human SAA1. Presumptive identification of calcium and lipid binding sites. |
| Q58853192 | Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis |
| Q37191107 | Serum C-reactive protein concentration in the management of infection in patients treated by continuous ambulatory peritoneal dialysis |
| Q69860132 | Serum C-reactive protein in polymyalgia rheumatica. A prospective serial study |
| Q71226485 | Serum C-reactive protein in primary Sjögren's syndrome |
| Q40828855 | Serum C-reactive protein levels in the management of infection in acute leukaemia |
| Q33555821 | Serum C-reactive protein measurement in the detection of intercurrent infection in Oriental patients with systemic lupus erythematosus |
| Q54439934 | Serum C-reactive protein response to therapeutic embolisation: possible role in management. |
| Q69340278 | Serum amyloid A protein (SAA) in horses: objective measurement of the acute phase response |
| Q73060570 | Serum amyloid A protein is a clinically useful indicator of acute renal allograft rejection |
| Q78060030 | Serum amyloid P component (not serum amyloid protein) |
| Q41851496 | Serum amyloid P component binds to cell nuclei in vitro and to in vivo deposits of extracellular chromatin in systemic lupus erythematosus |
| Q56595317 | Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity |
| Q67833572 | Serum amyloid P component in chronic renal failure and dialysis |
| Q24562844 | Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis |
| Q34366234 | Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis |
| Q47851173 | Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation |
| Q71617193 | Serum amyloid P-component and C-reactive protein in serum of healthy Icelanders and members of an Icelandic family with macroglobulinaemia |
| Q41461262 | Serum amyloid P-component is an acute-phase reactant in the mouse |
| Q72530541 | Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis |
| Q71704625 | Serum concentrations of C-reactive protein and serum amyloid P component in plaice (Pleuronectes platessa L.) in relation to season and injected lipopolysaccharide |
| Q71628528 | Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis |
| Q72075971 | Serum protein concentrations during Schistosoma mansoni infection in intact and T-cell deprived mice. I. The acute phase proteins, C3 and serum amyloid P-component (SAP) |
| Q71695785 | Significance of CRP elevation in SLE |
| Q71082547 | Solid phase radioimmunoassays for human C-reactive protein |
| Q70404696 | Solid-phase immunoradiometric assay for C-reactive protein using magnetisable cellulose particles |
| Q70604600 | Solid-phase immunoradiometric assay for serum amyloid A protein using magnetisable cellulose particles |
| Q34248321 | Specific chemical dissociation of fibrillar and non-fibrillar components of amyloid deposits |
| Q36354563 | Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component |
| Q41630822 | Structural diversity of ex vivo amyloid fibrils studied by cryo-electron microscopy |
| Q27731194 | Structure of pentameric human serum amyloid P component |
| Q37312131 | Structure, folding dynamics, and amyloidogenesis of D76N β2-microglobulin: roles of shear flow, hydrophobic surfaces, and α-crystallin. |
| Q68298681 | Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis |
| Q67507672 | Studies in vivo of cobra factor and murine C3 |
| Q71263425 | Studies of human serum amyloid P-component (SAP) in relation to coagulation |
| Q69882978 | Studies of the in vivo synthesis and catabolism of serum amyloid P component (SAP) in the mouse |
| Q71609687 | Studies of the structure and binding properties of hamster female protein |
| Q45825222 | Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis |
| Q28217930 | Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis |
| Q95418677 | Targeted treatment for amyloidosis |
| Q33995386 | Targeting C-reactive protein for the treatment of cardiovascular disease. |
| Q39432383 | Temperature dependence of antigen-specific rosette formation by lymphocytes from immunised mice |
| Q54014234 | Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. |
| Q48054078 | The MHC class II-restricted T cell response of C57BL/6 mice to human C-reactive protein: homology to self and the selection of T cell epitopes and T cell receptors |
| Q58230388 | The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina |
| Q72739009 | The acute phase response in parasite infection. Nippostrongylus brasiliensis in the mouse |
| Q36346930 | The acute-phase response in (NZB X NZW)F1 and MRL/l MICE. |
| Q72497883 | The effect of inflammatory agents on C-reactive protein and serum amyloid P-component levels in plaice (Pleuronectes platessa L.) serum |
| Q70584375 | The failure of ascorbic acid therapy to alter the induction or remission of murine amyloidosis |
| Q47733783 | The first international standard for serum amyloid A protein (SAA). Evaluation in an international collaborative study |
| Q40622328 | The genetic basis of autosomal dominant familial Mediterranean fever |
| Q35350650 | The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients |
| Q34188358 | The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo |
| Q27618638 | The physiological structure of human C-reactive protein and its complex with phosphocholine |
| Q57843307 | The protofilament substructure of amyloid fibrils11Edited by F. E. Cohen |
| Q42770077 | The renaissance of C reactive protein |
| Q27639384 | The structures of crystalline complexes of human serum amyloid P component with its carbohydrate ligand, the cyclic pyruvate acetal of galactose |
| Q34485172 | Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component |
| Q27732605 | Three dimensional structure of human C-reactive protein |
| Q28610060 | Tissue Vitronectin in Normal Adult Human Dermis Is Non-Covalently Bound to Elastic Tissue |
| Q69934732 | Tissue amyloid P component in normal human dermis is non-covalently associated with elastic fiber microfibrils |
| Q42514204 | Tolerance and immunity to the inducible self antigen C-reactive protein in transgenic mice |
| Q30475959 | Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. |
| Q34641225 | Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice |
| Q48267730 | Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis |
| Q72012225 | Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy |
| Q27665687 | Trapping of palindromic ligands within native transthyretin prevents amyloid formation |
| Q72574019 | Treatment of Wegener's granulomatosis |
| Q34720995 | Treatment of amyloidosis |
| Q70289631 | Ultrastructural localization of amyloid P component in primary localized cutaneous amyloidosis |
| Q34591172 | Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease |
| Q33552323 | Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus |
| Q68970234 | X-ray scattering and diffraction by wet gels of AA amyloid fibrils |
| Mark Pepys | wikipedia |
Search more.